上海萊士(002252.SZ):萊士中國被動減持4800萬股
格隆匯8月24日丨上海萊士(002252.SZ)公佈,公司收到 RAAS China Limited (萊士中國有限公司,“萊士中國”)出具的《關於協助披露萊士中國被動減持上海萊士股份的函》,萊士中國原質押給華鑫國際信託股份有限公司(“華鑫信託”)的4800萬股上海萊士股份因逾期未還款被上海金融法院強制執行。上述4800萬股上海萊士股份於2021年7月15日被司法拍賣併成交,並於2021年8月23日在中國證券登記結算有限責任公司完成司法過户手續。萊士中國因此被動減持上海萊士股份4800萬股,占上海萊士總股本的0.71%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.